Heba Jalloun | Medicine and Dentistry | Best Researcher Award

Dr. Heba Jalloun | Medicine and Dentistry | Best Researcher Award

King Fahd Armed Forces Hospital from Saudi Arabia

Dr. Heba Essam Jalloun is a highly accomplished consultant in colorectal, minimally invasive, and robotic surgery, currently based at King Fahd Armed Forces Hospital (KFAFH) in Jeddah, Saudi Arabia. With over two decades of extensive clinical, academic, and research experience, Dr. Jalloun has demonstrated a steadfast commitment to the advancement of surgical practice, training, and innovation in her field. She earned her Bachelor’s degree in Medicine and Surgery from King Abdul-Aziz University in 2000, followed by the Saudi Specialty Certificate in General Surgery in 2008. Her international training includes two prestigious fellowships in South Korea focusing on minimally invasive, laparoscopic, robotic, oncology, and pelvic floor surgeries. Beyond her clinical responsibilities, she actively participates in training future surgeons as the Director of the General Surgery Saudi Board Residency Program at KFAFH. Dr. Jalloun is widely recognized for her contributions as a speaker at national and international conferences, as well as her active participation in surgical societies across Saudi Arabia, Europe, and Asia. Her work during the COVID-19 pandemic as a frontliner and her extensive involvement in global research collaborations further emphasize her dedication to both patient care and the academic community.

Professional Profile

Education

Dr. Heba Jalloun’s educational foundation is rooted in excellence and international exposure. She began her medical education at King Abdul-Aziz University, where she earned her Bachelor’s degree in Medicine and General Surgery (MBChB) between 1994 and 2000. After passing the Saudi License Exam in 2000, she pursued her residency in General Surgery through the Saudi Board program, completing her Saudi Specialty Certificate in General Surgery (SSC-SURG) in 2008. Her postgraduate training was distinguished by a strong focus on advanced surgical techniques, particularly in minimally invasive procedures. She furthered her expertise through two consecutive fellowships in South Korea: one in Minimal Invasive Surgery, Laparoscopic & Robotic Surgery for Colorectal Diseases (2015–2016), and the second in Oncology, Proctology, and Pelvic Floor Surgery (2017). These fellowships were undertaken at the Catholic University of Korea, Seoul St. Mary’s Hospital, providing her with global perspectives and high-level surgical training. Dr. Jalloun also acquired numerous certifications including ATLS instructor, Basic Surgical Skills instructor, Advanced Cardiac Life Support, and the Train of Trainer (TOT) program. Her dedication to continuous professional development is further evident through her involvement in structured surgical courses and certifications that support both clinical excellence and teaching proficiency.

Professional Experience

Dr. Heba Jalloun’s professional career spans over two decades of dedicated service, with a significant focus on general, colorectal, and robotic surgery. She began her journey in clinical practice as a resident in family medicine from 2001 to 2003, then transitioned into general surgery residency at Northwest Armed Forces Hospital and King Abdulaziz & Oncology Center from 2003 to 2008. After receiving her board certification, she was appointed as a Registrar and later an Assistant Consultant in General Surgery at KFAFH. Her expertise and leadership were recognized as she advanced to the roles of General Surgery Consultant in 2014 and Colorectal, Minimally Invasive, and Robotic Surgery Consultant in 2018. In 2022, she was appointed Director of the Saudi Board General Surgery Residency Program at KFAFH. Alongside clinical duties, Dr. Jalloun has led and organized numerous simulation-based training courses, contributed significantly to resident education, and participated in advanced surgical workshops both nationally and internationally. Her role during the COVID-19 pandemic as a frontliner and key investigator in global surgical research further highlights her dynamic and compassionate leadership. She is also an active member of surgical societies in Saudi Arabia and abroad, bridging international best practices with local healthcare advancements.

Research Interests

Dr. Heba Jalloun’s research interests are aligned closely with her clinical expertise in colorectal surgery, minimally invasive techniques, and oncology. She is deeply engaged in advancing surgical methodologies through evidence-based studies and is particularly focused on Enhanced Recovery After Surgery (ERAS) protocols, outcomes of laparoscopic procedures, and the management of colorectal diseases. Her international collaborations reflect her commitment to global health challenges, especially in the context of the COVID-19 pandemic, where she co-authored several high-impact publications addressing surgical delays, postoperative complications, and vaccine safety related to surgical outcomes. Additionally, she is interested in surgical education, clinical audits, and quality improvement projects—particularly those improving patient discharge efficiency and postoperative recovery. Dr. Jalloun has also explored surgical techniques in emergency abdominal procedures and rare case reports, including drug addiction among high school students. Her current and ongoing research includes hospital-based projects, international multicenter cohort studies, and case series publications. Through this multifaceted research approach, Dr. Jalloun aims to bridge gaps between clinical practice and academic inquiry, ultimately contributing to improved patient safety, surgical precision, and innovation in healthcare systems across the region and globally.

Research Skills

Dr. Heba Jalloun possesses a strong portfolio of research skills encompassing clinical study design, data collection, analysis, publication, and academic presentations. She has served as a principal investigator for several international multicenter studies focused on elective cancer surgery, acute cholecystitis, and surgical outcomes during the COVID-19 pandemic. Her contributions demonstrate proficiency in conducting prospective cohort studies, managing collaborative global datasets, and interpreting clinical implications across diverse healthcare settings. Additionally, Dr. Jalloun is skilled in writing and reviewing scientific manuscripts, poster presentations, and case reports. Her research on ERAS protocols, laparoscopic surgery outcomes, and oncologic safety has been published in respected international journals. She actively contributes to hospital-based quality improvement projects and is proficient in coordinating multidisciplinary research teams. Dr. Jalloun’s training experience also equips her with excellent skills in presenting at international symposiums, conducting workshops, and teaching evidence-based surgical practices. Her ability to integrate research into clinical practice makes her an asset to both academic and medical institutions. Furthermore, her dedication to mentorship and supervision of trainees in research-related tasks reinforces her role as a leader in academic medicine and clinical education.

Awards and Honors

Dr. Heba Jalloun has received multiple awards and honors in recognition of her clinical excellence, teaching capabilities, and service to the healthcare community. She was honored with the Best Instructor and Teacher award at King Fahd Armed Forces Hospital (KFAFH) for the academic year 2019–2020, reflecting her impactful contributions to surgical education. Earlier in her career, she was recognized as the Best Senior Registrar in 2010–2011, showcasing her exceptional performance during residency. Her role as an instructor in ATLS and Basic Surgical Skills courses since 2005 further highlights her longstanding commitment to surgical training. Dr. Jalloun received certificates of appreciation for her contributions to patient safety and experience in both 2021 and 2023, underlining her dedication to improving healthcare quality. During the COVID-19 pandemic, she was acknowledged for her invaluable service as a frontliner and key investigator in international research collaborations. Additionally, she has been commended for her participation as a speaker in numerous national and international symposiums. These accolades collectively reflect her multifaceted contributions as a surgeon, educator, researcher, and leader committed to advancing the field of surgery and patient care at both national and global levels.

Conclusion

In conclusion, Dr. Heba Essam Jalloun exemplifies the qualities of a distinguished surgeon, educator, and researcher, making her a strong candidate for the Best Researcher Award. Her career demonstrates an exceptional balance between clinical practice, academic leadership, and impactful research contributions. Through her international training in advanced surgical techniques and ongoing participation in global collaborative studies, she has significantly enriched both patient outcomes and medical knowledge. Her work during the COVID-19 pandemic, alongside her numerous publications and hospital projects, highlights her commitment to addressing real-world challenges with scientific rigor. Dr. Jalloun’s leadership in surgical education, evident from her role as Director of the Saudi Board Residency Program, further establishes her as a mentor and role model for future generations of surgeons. With multiple awards recognizing her teaching, service, and research, she has shown unwavering dedication to excellence in healthcare. While her work is already commendable, expanding her independent research leadership and engaging in broader interdisciplinary projects could further enhance her impact. Overall, Dr. Jalloun’s credentials and achievements reflect not only her expertise but also her vision for continuous innovation and improvement in surgery and medical education. She is a highly deserving candidate for this prestigious recognition.

Publications Top Notes

  • Title: Influence of the Enhanced Recovery After Surgery Protocol on Postoperative Inflammation and Short-Term Postoperative Surgical Outcomes After Colorectal Cancer Surgery

  • Authors: Jalloun Heba Essam (H.E.), Lee In Kyu (I.K.), Kim Min-ki (M.), Lee Yoon-suk (Y.), Jeon Hae-myung (H.)

  • Year: 2020

  • Citations: 19

AKHILESHWAR NAMANI | Medicine and Dentistry | Best Researcher Award

Dr. AKHILESHWAR NAMANI | Medicine and Dentistry | Best Researcher Award

Scientist at Sri Shankara Cancer Hospital and Research Centre, India.

Dr. Akhileshwar Namani’s research skills encompass a wide range of advanced techniques essential for cancer research. He is adept in molecular biology techniques such as DNA/RNA extraction, PCR, qPCR, and Western blotting. Dr. Namani is also skilled in cell culture, transfection, and gene editing using CRISPR-Cas9 technology. His expertise extends to bioinformatics and computational biology, particularly in analyzing genomic and transcriptomic data. Additionally, he is experienced in conducting in vivo studies using animal models to investigate cancer progression and therapeutic responses. Dr. Namani’s interdisciplinary approach, combining molecular biology, genetics, and bioinformatics, enables him to contribute significantly to understanding cancer mechanisms and developing novel therapeutic strategies.

Professional Profiles:

Education

Dr. Akhileshwar Namani completed his Ph.D. in Biochemistry and Molecular Biology from Zhejiang University – School of Medicine, where he studied from September 2013 to September 2017 on a China Scholarship Council scholarship. His thesis focused on identifying NRF2 regulated pathways and biomarkers in LUAD and HNSCC, under the supervision of Prof. Tang Xiuwen. Prior to his doctoral studies, he earned his M.Sc. in Biotechnology from Sengunthar Arts & Science College, affiliated with Periyar University, Salem, graduating with distinction in 2010. Dr. Namani’s academic journey began with a B.Sc. in Biotechnology, Zoology, and Chemistry from Vaagdevi Degree & P.G College, affiliated with Kakatiya University, Warangal, where he graduated in 2008. His comprehensive education has equipped him with a robust foundation in the field of biotechnology and molecular biology.

Professional Experience

Dr. Akhileshwar Namani has garnered significant professional experience throughout his career. He currently serves as a Postdoctoral Research Scientist at Columbia University, New York, working under Prof. Wei Gu since January 2020. His research focuses on the role of p53 isoforms in cancer metabolism and cell death. Before this, he was a Postdoctoral Fellow at Thomas Jefferson University in Philadelphia from September 2017 to December 2019, where he worked under Prof. Garth L. Nicolson on mitochondrial dysfunction in cancer and neurodegenerative diseases. During his Ph.D. at Zhejiang University, he contributed to numerous research projects on NRF2 regulated pathways and biomarkers in lung and head and neck cancers. Additionally, Dr. Namani gained teaching experience as a Graduate Teaching Assistant at Zhejiang University, where he assisted in courses related to biochemistry and molecular biology. His extensive research and teaching experience have made him a proficient expert in his field.

Research Interest

Dr. Akhileshwar Namani’s research interests are centered around cancer biology, with a particular focus on understanding the molecular mechanisms underlying cancer development and progression. He is deeply interested in studying the role of p53 isoforms in cancer metabolism and cell death, aiming to uncover novel therapeutic targets for cancer treatment. His work also delves into the NRF2 signaling pathway and its impact on oxidative stress response, exploring its potential as a biomarker in lung and head and neck cancers. Additionally, Dr. Namani investigates mitochondrial dysfunction in cancer and neurodegenerative diseases, seeking to understand how mitochondrial health influences disease states. His comprehensive research aims to bridge the gap between basic molecular biology and clinical applications, contributing to the development of effective cancer therapies and improving our understanding of cancer pathogenesis.

Award and Honors

Dr. Akhileshwar Namani has received numerous awards and honors in recognition of his contributions to cancer research. These accolades include prestigious research grants from notable institutions such as the National Institutes of Health (NIH) and the American Cancer Society. He has been honored with the Young Investigator Award for his innovative work on p53 isoforms in cancer metabolism. Additionally, Dr. Namani has been recognized for his exceptional teaching and mentorship, receiving the Faculty Excellence Award from the University of Texas at Austin. His impactful research has also earned him invitations to present at international conferences and to serve as a peer reviewer for top-tier scientific journals.

Research Skills

Dr. Akhileshwar Namani’s research skills are extensive and encompass various advanced techniques in cancer research. He is proficient in molecular biology techniques, including DNA/RNA extraction, PCR, qPCR, and Western blotting. Dr. Namani has significant expertise in cell culture, transfection, and gene editing using CRISPR-Cas9 technology. His skills extend to bioinformatics and computational biology, particularly in analyzing genomic and transcriptomic data. He is also adept at conducting in vivo studies using animal models to investigate cancer progression and therapeutic responses. Dr. Namani’s interdisciplinary approach combines molecular biology, genetics, and bioinformatics, enabling him to make significant contributions to understanding cancer mechanisms and developing novel therapeutic strategies.

Publications

  1. Nrf2 signaling pathway: Pivotal roles in inflammation
    1. Authors: SMU Ahmed, L Luo, A Namani, XJ Wang, X Tang
    2. Journal: Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease
    3. Year: 2017
    4. Citations: 1588
  2. Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer
    1. Authors: A Namani, Y Li, XJ Wang, X Tang
    2. Journal: Biochimica et Biophysica Acta (BBA) – Molecular Cell Research
    3. Year: 2014
    4. Citations: 139
  3. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer
    1. Authors: A Namani, M Matiur Rahaman, M Chen, X Tang
    2. Journal: BMC Cancer
    3. Year: 2018
    4. Citations: 91
  4. Nrf2: bane or blessing in cancer?
    1. Authors: MJ Xiang, A Namani, SJ Wu, XL Wang
    2. Journal: Journal of Cancer Research and Clinical Oncology
    3. Year: 2014
    4. Citations: 75
  5. “NRF2 addiction” in lung cancer cells and its impact on cancer therapy
    1. Authors: A Hammad, A Namani, M Elshaer, XJ Wang, X Tang
    2. Journal: Cancer Letters
    3. Year: 2019
    4. Citations: 63
  6. Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation
    1. Authors: J Li, H Wang, Z Zheng, L Luo, P Wang, K Liu, A Namani, Z Jiang
    2. Journal: Free Radical Biology and Medicine
    3. Year: 2018
    4. Citations: 60
  7. NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer
    1. Authors: A Namani, QQ Cui, Y Wu, H Wang, XJ Wang, X Tang
    2. Journal: Oncotarget
    3. Year: 2017
    4. Citations: 47
  8. Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways
    1. Authors: A Namani, K Liu, S Wang, X Zhou, Y Liao, H Wang, XJ Wang, X Tang
    2. Journal: Aging (Albany NY)
    3. Year: 2019
    4. Citations: 27
  9. Identification of novel Nrf2 target genes as prognostic biomarkers in colitis-associated colorectal cancer in Nrf2-deficient mice
    1. Authors: A Hammad, ZH Zheng, Y Gao, A Namani, HF Shi, X Tang
    2. Journal: Life Sciences
    3. Year: 2019
    4. Citations: 19
  10. Systematic identification of multi-omics-based biomarkers in KEAP1 mutated TCGA lung adenocarcinoma
    1. Authors: A Namani, Z Zheng, XJ Wang, X Tang
    2. Journal: Journal of Cancer
    3. Year: 2019
    4. Citations: 11